HemaVision develops and industrializes a technological platform for the cellular quality control market, based on a patented cell‑labeling process and three‑dimensional morphological cell analysis. This modeling is converted into actionable, industry‑ready indicators to anticipate production anomalies in cell therapies, bioproduction, and cell culture processes, with mid‑term applications in blood products and broader biomedical fields.